<治療に関する研究>M-SHRSPの高血圧性腎病変に対するカルシウム拮抗剤KW-3049の治療効果

概要

論文の詳細を見る
It has been reported that calcium antagonists have the potential to protect kidneys from hypertension. However, the therapeutic effect of calcium antagonists on kidneys (especially in malignant hypertension) is not quite clear. Using M-SHRSP, this pathological and biochemical study was performed to evaluate the renal effect of a calcium antagonist in malignant hypertension. Eleven-week-old male M-SHRSP were used. A calcium antagonist (KW-3049) was administered orally at daily dosages of 10mg or 20mg/kg/day via catheter. The treatment continued for five weeks. Excretion of urinary albumin and glucose, serum concentrations of creatinine (CRE), blood urea nitrogen (BUN), albumin (ALB), and glucose (GLU) were measured. For control group rats, the blood pressures were over 250 mmHg and the urinary excretions of albumin and glucose were abundant, and serum albumin concentrations and creatinine clearances (CCR) were low while BUN concentrations were high. However, in both treatment groups, blood pressure decreased to less than 150 mmHg within 6 hours following administration, but then increased gradually to more than 250 mmHg by 24 hours after the administration. Urinary excretions of albumin and glucose were significantly less than those of the control rats. Levels of serum albumin, CCR and BUN were within normal ranges. Pathological results showed that control rats had high frequencies of hypertensive vascular lesions with degenerated and/or atrophic urinary tubules and glomerulus collapse. However, in both treatment groups, the incidence of such hypertensive lesions was much lower than that of the control rats. These findings suggest that KW-3049 may be advantageous for kidney hypertensive vascular lesions and for repairing and/or protecting renal structures and functions.
近畿大学の論文
1994-12-30

<治療に関する研究>M-SHRSPの高血圧性腎病変に対するカルシウム拮抗剤KW-3049の治療効果

スポンサーリンク

概要

著者

関連論文

スポンサーリンク